An active substance binds to its cellular target structure. Credit: Daniel Rauh

About 1,200 Germans are diagnosed with gastrointestinal stromal tumors every year—a rare type of cancer in which the tumors develop in the walls of the digestive organs and quickly develop resistance to common precision drugs.

Scientists at TU Dortmund University, the West German Tumor Center Essen and the Max Planck Institute of Molecular Physiology in Dortmund have identified a promising active substance against gastrointestinal stromal tumors, applied for a patent and licensed it to a U.S. pharmaceutical company, which now wants to develop it further until it is ready for the market—an important step on the path from basic research to clinical application.

The teams led by Daniel Rauh from TU Dortmund University, Sebastian Bauer from the University of Duisburg-Essen and Sonja Sievers, Head of the Compound Management and Screening Center (COMAS) at the Max Planck Institute of Molecular Physiology identified a chemical substance that proved to be highly effective against drug-resistant gastrointestinal stromal tumor cells in preclinical laboratory tests.

The universities and the Max Planck Institute filed a patent application for the active substance and with the help of PROvendis, the commercialization company of 29 NRW universities, it was immediately licensed out to a U.S. pharmaceutical company, which will drive forward clinical development.

“This success shows the enormous potential of drug research within the University Alliance Ruhr,” says Daniel Rauh. “The development of a new drug usually takes 10 years or longer. The special thing about this success is that the compound was already tested years ago with a different focus. At that time, however, it was not convincing. Now we are lucky enough to have rediscovered this substance.”

Central substance library of the Max Planck Society

“COMAS is the central substance library of the Max Planck Society and contains over 300,000 small molecules. In the current project, we have screened over 25,000 substances from this molecular treasure trove and were able to find the promising drug against gastrointestinal stromal tumors. Our setup, which is unique in Germany, makes it possible to translate research results into medical applications,” says Sonja Sievers, Head of COMAS.

The cell cultures for preclinical testing of the potential active substances were established at the West German Tumor Center. “Modern molecular biology methods such as gene scissors enable us to reproduce molecular variants of the tumors of our patients in the laboratory in a very short time. We have thus established a dynamically growing model library that is unique in this form worldwide,” says Sebastian Bauer.

“The identification of our substance is therefore the result of integrated innovation cycles within the UA Ruhr that have grown over the years.”

As gastrointestinal stromal tumors are very dynamic, resistance to the rediscovered substance is also likely to develop. The interdisciplinary team from the fields of molecular genetics, cell biology, high-throughput screening, structural biology and organic synthesis is therefore already working on successor substances.

Provided by Max Planck Society